Menu

Impact Events

More
Date Lead Company Event Type Approval Change Approval Likelihood
5/22/26 Roche (RO) giredestrant for Breast Cancer Subscribers Only Subscribers Only Subscribers Only
5/22/26 Roche (RO) giredestrant for HR+/HER2- Breast Cancer Subscribers Only Subscribers Only Subscribers Only
5/21/26 Rigel Pharmaceuticals (RIGL) Gavreto for Non-Small Cell Lung Cancer (NSCLC) Subscribers Only Subscribers Only Subscribers Only
5/21/26 Merck KGaA (MKKGY) Bavencio for Neuroendocrine Tumors (NET) Subscribers Only Subscribers Only Subscribers Only
5/21/26 Merck KGaA (MKKGY) Bavencio for Colorectal Cancer (CRC) Subscribers Only Subscribers Only Subscribers Only

Upcoming Catalysts

More
Expected Date Range Lead Company Drug Expected Catalyst
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/25/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
06/26/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update
07/31/2025 Subscribers Only Subscribers Only Regulatory - IND/CTA Filing
09/08/2025 Subscribers Only Subscribers Only Company - Analyst/R&D Update